Evidence map›Paper›PMID 40153157›Full record

ReviewMolecular diversity2025

An updated survey on the recent advancement of antimalarial molecules: synthetic methodologies and SAR studies.

Hamna Nawaz, Ayesha Malik, Nasir Rasool, Aqsa Kanwal, Tahira Khalid, Iffat Almas, Samreen Gul Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hamna NawazDepartment of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
Ayesha MalikDepartment of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan. ayesha.m726@gmail.com.
Nasir RasoolDepartment of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
Aqsa KanwalDepartment of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
Tahira KhalidDepartment of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
Iffat AlmasDepartment of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
Samreen Gul KhanDepartment of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An ongoing escalation in malaria cases is a critical global health issue and also a leading source of increased mortality rates. Infected mosquitos spread the Plasmodium parasite-based disease,. Recent advancements in antimalarial drug discovery have focused on developing novel molecules with unique mechanisms of action to combat this growing resistance. This review focuses on the latest findings in synthesizing hybrid antimalarial compounds, which combine different pharmacophores to enhance therapeutic efficacy, resulting in compounds that exhibit potent action against both resistant/sensitive strains of chloroquine, quinine, and artemisinin. Notably, the incorporation of diverse scaffolds such as 1,2,4-trioxanes, halogenated quinolines, pyrazoline, and sulfonamides has led to promising candidates that not only demonstrate high potency but also favorable pharmacokinetic profiles for drug development, the exploration of novel targets. This review highlights the progress (2019-2024) made in identifying and synthesizing hybrid antimalarial molecules while addressing existing challenges in the field.

Indexed as

AntimalarialsAnimalsDrug DiscoveryHumansMalariaPlasmodiumStructure-Activity RelationshipAntimalarials1,2,4-trioxanes; ArtemisininAntimalarial agentsMultidrug-resistantP. falciparum 3D7/KI strainsP. yoelii nigeriensisSchiff base metal complexesStructure–activity relationship

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.